NCT06840834 (Bi-MAPS) is a Phase 2 clinical trial of Ivonescimab in Pleural Mesotheliomas, sponsored by Intergroupe Francophone de Cancerologie Thoracique.

Who is sponsoring NCT06840834?

NCT06840834 is sponsored by Intergroupe Francophone de Cancerologie Thoracique.

What drugs are being tested in NCT06840834?

Interventions in NCT06840834: Ivonescimab.

What condition does NCT06840834 study?

NCT06840834 studies Pleural Mesotheliomas.

Is NCT06840834 still recruiting?

NCT06840834 is currently recruiting now. Last updated 16 March 2026.

Last reviewed 2026-03-16 · How we verify

NCT06840834: Bi-MAPS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy

Recruiting now Phase 2 Last updated 16 March 2026

What this trial tests

Phase 2 trial testing Ivonescimab in Pleural Mesotheliomas in 38 participants. Currently enrolling.

Timeline

30 June 2025

Primary endpoint
24 March 2026

31 March 2028

Quick facts

Lead sponsor	Intergroupe Francophone de Cancerologie Thoracique
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	38
Start date	30 June 2025
Primary completion	24 March 2026
Estimated completion	31 March 2028
Sites	20 locations across France

Drugs / interventions tested

Ivonescimab — full drug profile →

Conditions studied

Pleural Mesotheliomas — all drugs for Pleural Mesotheliomas →

Sponsor

Intergroupe Francophone de Cancerologie Thoracique — full company profile →

Who can join

18 and older, any sex, with Pleural Mesotheliomas. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Multicentre, open-label, single arm phase II study for patients with PM previously treated by immunotherapy and standard chemotherapy. 38 patients will be given second or third-line treatment with ivonescimab 20mg/kg every 3 weeks. An estimated 38 patients will be enrolled in approximately 20 centres. Patients will be treated for a maximum of 2 years, until disease progression, unacceptable toxicity, withdrawal of consent or another discontinuation criterion is met. The null hypothesis is disease control rate (DCR) at 12 weeks ≤ 30%. The alternative hypothesis is DCR ≥ 55% at 12 weeks.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Moving Beyond Morphology: Toward a Morpho-Molecular Classification of Pleural Mesothelioma.
Drevet G, Kalson L, Mangé L, Galateau-Salle F, et al · · 2026 · cited 1× · PMID 41718511 · DOI 10.1016/j.jtho.2026.01.003
From biology to therapy: current standards and emerging strategies in pleural mesothelioma.
van Genugten JHLT, de Gooijer CJ, Baas P. · · 2026 · PMID 41971442 · DOI 10.3389/fonc.2026.1778121

Verify or expand the search:

Other trials of Ivonescimab

Trials testing the same drug.

NCT07405190 — Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC · Phase 2 · not yet recruiting
NCT07363408 — Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment · Phase 1 · not yet recruiting
NCT07226544 — Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer · Phase 2 · not yet recruiting
NCT07472478 — Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12 · Phase 2 · not yet recruiting
NCT06951646 — ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immuno · Phase 2 · recruiting

Other Intergroupe Francophone de Cancerologie Thoracique trials

Trials by the same sponsor.

NCT07420439 — Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease · Phase 2 · not yet recruiting
NCT06937905 — Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic P · Phase 3 · recruiting
NCT06908993 — Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Trea · Phase 3 · recruiting
NCT05285033 — RW Effectiveness of Lurbinectedin in Extensive Stage SCLC · completed
NCT05273047 — RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06840834 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Intergroupe Francophone de Cancerologie Thoracique
Last refreshed: 16 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06840834.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing